Navigation Links
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Date:3/11/2011

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.  

Following preliminary review of the data, no new or unexpected treatment-related safety concerns have emerged during the DEFEND-1 study. Study investigators and regulatory agencies have been notified of the DEFEND-1 study outcome.

GSK will continue to explore additional dosing regimens to inform decisions about the future clinical development programme for otelixizumab.  New recruitment and dosing in the DEFEND-2 study, the ongoing confirmatory Phase 3 study with a design similar to DEFEND-1, has been suspended pending review of the DEFEND-1 results.

"While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx. "Our immunotherapy candidates represent some of the latest scientific advances in harnessing the immune system for therapeutic benefit, including TRX518 which is a showpiece of our pipeline as an immunotherapy to treat cancer."

"Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward," said Jackie Parkin, Medicines Development Leader, GlaxoSmithKline.

Tolerx Pipeline

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
3. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
4. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
5. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
8. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
9. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. GlaxoSmithKline Wins Environmental Stewardship Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... de 2015 BGI anunció hoy que su ... rendimiento en Hong Kong ha ... instalación de BGI en Hong Kong ... generación que recibe la certificación CAP en ... prácticas de laboratorio clínico. Junto con el exitoso proceso ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/9q4d5d/veterinary_ ) has ... Vaccines Market by Product, Diseases & Technology - Global ... The global animal vaccines market is poised to ... 2015, at a CAGR of 5.5% from 2015 to ... growing prevalence of animal diseases, increasing incidences of zoonotic ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
Breaking Medicine Technology:BGI recibe la acreditación del College of American Pathologists (CAP) 2Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... Nycomed US Inc. today announced the appointment of Steve Andrzejewski ... US Inc., including manufacturing in Melville and Hicksville, New ... divisions Fougera, PharmaDerm and Savage Laboratories. , ... Steve Andrzejewski has been working in the ...
... 2010 Today, Novo Nordisk announced the,landmark recruitment of the 60,000th patient in ... in,the management of type 2 diabetes.[1] , , ... Spanning 28 countries across 4 continents and involving more than 3300,physicians, A1chieve(R) ... , , ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief operating officer recruitment for Nicklaus Children’s Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... ... 2015 , ... Throughout the month of April, Casey’s General Stores invited customers ... Tuesday, July 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a ... a national nonprofit dedicated to restoring a sense of self, restoring the family unit, ...
(Date:7/2/2015)... ... July 02, 2015 , ... AvePoint Public Sector, Inc., a ... platforms and devices, today announced it was named the recipient of the 2015 GTRA ... award, given out by the Government Technology Research Alliance (GTRA), was presented June 29 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it has made two key appointments at ... General Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid ...
Breaking Medicine News(10 mins):Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... Arizona State University has used molecular biology tricks to create ... the ones that occurred naturally. ,John ... proteins in a fraction of the three billion years it ... to some surprisingly new lessons on how to optimize proteins ...
... University of Nottingham experts have joined forces with Canadian ... weapons in the fight against food poisoning . ... to develop methods for the control of Campylobacter ... England and Wales, according to the Health Protection Agency. ...
... a child is a uniquely enjoyable process. Why spoil it ... midwives, ask freebirthers . ,Delivering their own babies ... "fearmongering" by doctors and midwives and confidently catch their own ... uses the same hormones as lovemaking - so why would ...
... expectant mothers who smoke during pregnancy may be exposing ... disorder (ADHD), according to a study published in the ... prenatal exposure to smoking in the mothers womb puts ... ,During the course of study, the ...
... years ago, retail pioneer and philanthropist A. Alfred Taubman lost ... fatal disease thats better known as Lou Gehrigs disease or ... Sen. Jacob Javits slowly succumb to the nerve-killing condition has ... him to support ALS research at the University of Michigan ...
... seeking to prosecute director Michael Moore for taking volunteers on ... admission from New Yorks civic authorities. ,City's chief ... from the twin towers contributed to the death of Felicia ... Sept. 11 as she ran from her office a block ...
Cached Medicine News:Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:Delivering Baby, the Natural Way. 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 3Health News:Death from Exposure to WTC Dust Confirmed 2
... hydrophilic acrylic IOL is the newest advance ... with the patient and surgeon in mind. ... optic polymerically crosslinked with PMMA haptics to ... excellent visual performance and biocompatibility. The high ...
... : the 1st monobloc hard ... an exclusive and patented process ... designed the first single piece ... the FZ60. This technology warrantes ...
TRIPODE Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
Medicine Products: